600196 复星医药
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入20,441,9704.75%41,661,61341,067,19641,399,54043,951,547
减:营业总成本19,682,6284.12%40,087,32539,397,51241,284,07741,346,264
    其中:营业成本10,288,1891.63%20,800,10321,365,57421,595,30923,169,690
               财务费用531,063-17.06%1,153,4251,110,518984,323647,403
               资产减值损失(14,943)-76.75%(150,063)(96,570)(219,742)(272,488)
公允价值变动收益273,652-663.11%(322,268)(115,939)(427,380)(2,498,368)
投资收益1,493,305-29.57%3,763,7782,104,6073,501,9934,377,843
    其中:对联营企业和合营企业的投资收益1,135,35522.13%1,923,9791,643,8392,184,8491,835,146
营业利润2,615,941-5.26%5,228,3514,245,1043,307,5084,656,656
利润总额2,586,572-4.85%5,111,9834,169,2823,264,5684,574,382
减:所得税费用437,643-29.21%864,054656,841369,504626,917
净利润2,148,9282.32%4,247,9303,512,4402,895,0633,947,464
减:非控股权益427,4617.34%877,368742,554508,798216,660
股东净利润1,721,4681.15%3,370,5622,769,8872,386,2663,730,805

市场价值指针
每股收益 (元) *0.6501.56%1.2701.0400.8901.430
每股派息 (元) *----0.3900.3200.2700.420
每股净资产 (元) *18.2482.81%18.25217.70017.11016.684
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容